Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen
- PMID: 14532846
- DOI: 10.1097/01.ju.0000091264.46134.b7
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen
Abstract
Purpose: Prostate specific antigen (PSA) is a serine protease produced by the prostate gland at high concentrations. Serum PSA may be significantly elevated in prostate cancer and benign prostatic diseases. It has recently become evident that, in addition to being a tissue and/or serum marker, PSA may also have biological effects. Despite the voluminous literature on this biomarker in the diagnosis of prostatic diseases relatively few reports have addressed the issue of the physiological function, biological role and immune effects of PSA in the context of prostate cancer development and progression.
Materials and methods: Human dendritic cell (DC) cultures were generated from CD34+ hematopoietic precursors in the presence of PSA. The DC phenotype was assessed by flow cytometry and DC ability to induce T-cell proliferation was detected by allogeneic mixed lymphocyte reaction assay. DCs were also generated in co-cultures with LNCaP cells in the presence of antiPSA antibodies. The concentrations of PSA in cultures were determined by the AXSYM System (Abbott Laboratories, Wiesbaden, Germany).
Results: We noted that purified and LNCaP derived PSA inhibited the generation and maturation of DC (dendropoiesis) in vitro, which might have a crucial role in the induction and regulation of specific antitumor immune responses. The addition of active PSA to DC cultures significantly inhibited the generation and maturation of DC, as assessed by the levels of expression of CD83, CD80, CD86 and HLA DR. The ability of DC to induce T-cell proliferation, which depends on the expression of co-stimulatory and major histocompatibility complex molecules, was also suppressed in PSA treated DC cultures.
Conclusions: The antidendropoietic effect of PSA in vitro suggests a new mechanism of prostate cancer induced immunosuppression and tumor escape, and provides novel evidence of the immunoregulatory properties of PSA.
Similar articles
-
Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer.J Urol. 2002 Aug;168(2):741-7. J Urol. 2002. PMID: 12131362
-
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.Cancer Res. 2001 Jan 1;61(1):363-9. Cancer Res. 2001. PMID: 11196188
-
[Effects of ovarian carcinoma cells on the maturation and function of human dendritic cells].Zhonghua Yi Xue Za Zhi. 2009 Mar 10;89(9):630-4. Zhonghua Yi Xue Za Zhi. 2009. PMID: 19595165 Chinese.
-
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.Cancer Treat Rev. 2010 Apr;36(2):131-41. doi: 10.1016/j.ctrv.2009.11.002. Epub 2009 Dec 1. Cancer Treat Rev. 2010. PMID: 19954892 Review.
-
Antigen specificity of immune suppression by myeloid-derived suppressor cells.J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12. J Leukoc Biol. 2011. PMID: 21486906 Review.
Cited by
-
Tumor escape mechanisms in prostate cancer.Cancer Immunol Immunother. 2007 Jan;56(1):81-7. doi: 10.1007/s00262-005-0110-x. Epub 2005 Dec 16. Cancer Immunol Immunother. 2007. PMID: 16362411 Free PMC article. Review.
-
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Front Immunol. 2014 May 6;5:191. doi: 10.3389/fimmu.2014.00191. eCollection 2014. Front Immunol. 2014. PMID: 24834066 Free PMC article. Review.
-
Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance.Med Rev (2021). 2022 Feb 14;1(2):222-243. doi: 10.1515/mr-2021-0014. eCollection 2021 Dec. Med Rev (2021). 2022. PMID: 37724296 Free PMC article. Review.
-
Vaccination therapy in prostate cancer.Cancer Immunol Immunother. 2007 Apr;56(4):429-45. doi: 10.1007/s00262-006-0233-8. Epub 2006 Oct 10. Cancer Immunol Immunother. 2007. PMID: 17031640 Free PMC article. Review.
-
Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.Oncoimmunology. 2015 Mar 19;4(4):e1002720. doi: 10.1080/2162402X.2014.1002720. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26155387 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous